Home
Products & Services
Support
About
Contact Us
FinancialContent is the trusted provider of stock market information to the media industry.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Exelixis Inc (NQ: EXEL)
19.70 USD  -0.21 (-1.05%)
Official Closing Price  /  Updated: 6:03 PM EDT, Jun 14, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,970,400
Open 19.87
Bid (Size) 19.62 (3)
Ask (Size) 19.92 (10)
Prev. Close 19.91
Today's Range 19.67 - 19.93
52wk Range 13.42 - 25.31
Shares Outstanding 296,866,380
Dividend Yield N/A
Performance
YTD
-1.15%
-1.15%
1 Month
+1.91%
+1.91%
3 Month
-18.39%
-18.39%
6 Month
-5.47%
-5.47%
1 Year
+1.18%
+1.18%
Top News
More News
Exelixis Announces Webcasts of Investor Conference Presentations in June 2019
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be presenting at the following three investor conferences in June 2019: Read More
from Business Wire News Releases
Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into an exclusive option and license agreement with Iconic Therapeutics, Inc. (Iconic), a private biopharmaceutical company focused on... Read More
from Business Wire News Releases
More News
Read More
Exelixis Announces Webcasts of Investor Conference Presentations on May 21, 2019
from Business Wire News Releases
Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan
from Business Wire News Releases
Analysts Predict 17% Upside For PWC
category ETFs
from ETF Channel
Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinom
from Business Wire News Releases
Exelixis Announces First Quarter 2019 Financial Results and Provides Corporate Update
from Business Wire News Releases
Top 5 Stocks in the Fight Against Cancer
category Market News , BMY , BLUE , and 4 more.
from Motley Fool
Exelixis’ Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX® (Cabozantinib) for Advanced Renal Cell Carcinoma
from Business Wire News Releases
IBD Rating Upgrades: Exelixis Flashes Improved Price Strength
from Investor's Business Daily
Exelixis Inc Shares Down 12.9% Since SmarTrend's Sell Call (EXEL)
from Comtex SmarTrend® News Briefs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
© Copyright FinancialContent Services, Inc.